Sophie Dupuis-Girod

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6623015/publications.pdf

Version: 2024-02-01

46 papers 2,048 citations

279487 23 h-index 243296 44 g-index

48 all docs 48 docs citations

48 times ranked

1454 citing authors

#	Article	IF	CITATIONS
1	Embolization of Recurrent Pulmonary Arteriovenous Malformations by Ethylene Vinyl Alcohol Copolymer (Onyx®) in Hereditary Hemorrhagic Telangiectasia: Safety and Efficacy. Journal of Personalized Medicine, 2022, 12, 1091.	1.1	3
2	An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica, 2021, 106, 2161-2169.	1.7	64
3	Pulmonary hypertension in hereditary haemorrhagic telangiectasia is associated with multiple clinical conditions. ERJ Open Research, 2021, 7, 00078-2020.	1.1	4
4	Altered expressions of CXCR4 and CD26 on T-helper lymphocytes in hereditary hemorrhagic telangiectasia. Orphanet Journal of Rare Diseases, 2021, 16, 511.	1.2	0
5	Future treatments for hereditary hemorrhagic telangiectasia. Orphanet Journal of Rare Diseases, 2020, 15, 4.	1.2	76
6	Hereditary haemorrhagic telangiectasia and pregnancy: a review of the literature. Orphanet Journal of Rare Diseases, 2020, 15, 5.	1.2	25
7	Sequence variations of ACVRL1 play a critical role in hepatic vascular malformations in hereditary hemorrhagic telangiectasia. Orphanet Journal of Rare Diseases, 2020, 15, 254.	1.2	4
8	Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Annals of Internal Medicine, 2020, 173, 989-1001.	2.0	244
9	Intravenous Bevacizumab in Hereditary Hemorrhagic Telangiectasia: A Role That Is Still to Be Defined. Mayo Clinic Proceedings, 2020, 95, 1565-1566.	1.4	3
10	Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. Journal of Clinical Medicine, 2020, 9, 1262.	1.0	12
11	Classifying Ectopia Lentis in Marfan Syndrome into Five Grades of Increasing Severity. Journal of Clinical Medicine, 2020, 9, 721.	1.0	7
12	European Reference Network for Rare Vascular Diseases (VASCERN) position statement on cerebral screening in adults and children with hereditary haemorrhagic telangiectasia (HHT). Orphanet Journal of Rare Diseases, 2020, 15, 165.	1.2	28
13	Hereditary hemorrhagic telangiectasia and liver involvement. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 426-432.	0.7	5
14	Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial. Scientific Reports, 2019, 9, 11986.	1.6	13
15	Prevention of serious infections in hereditary hemorrhagic telangiectasia: roles for prophylactic antibiotics, the pulmonary capillaries-but not vaccination. Haematologica, 2019, 104, e85-e86.	1.7	11
16	Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet Journal of Rare Diseases, 2019, 14, 28.	1.2	75
17	12q13.12q13.13 microdeletion encompassing ACVRL1 and SCN8A genes: Clinical report of a new contiguous gene syndrome. European Journal of Medical Genetics, 2019, 62, 103565.	0.7	2
18	Recurrence of Hereditary Hemorrhagic Telangiectasia After Liver Transplantation: Clinical Implications and Physiopathological Insights. Hepatology, 2019, 69, 2232-2240.	3.6	21

#	Article	IF	CITATIONS
19	Pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia: Correlations between computed tomography findings and cerebral complications. European Radiology, 2018, 28, 1338-1344.	2.3	23
20	European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). Orphanet Journal of Rare Diseases, 2018, 13, 136.	1.2	74
21	The Lung in Hereditary Hemorrhagic Telangiectasia. Respiration, 2017, 94, 315-330.	1.2	55
22	Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. PLoS ONE, 2017, 12, e0188943.	1.1	57
23	Response to Bevacizumab for the treatment of Renduâ€Osler disease—A note of caution. Liver International, 2017, 37, 928-928.	1.9	2
24	Pulmonary hypertension subtypes associated with hereditary haemorrhagic telangiectasia: Haemodynamic profiles and survival probability. PLoS ONE, 2017, 12, e0184227.	1.1	21
25	Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia. JAMA - Journal of the American Medical Association, 2016, 316, 934.	3.8	54
26	Hereditary hemorrhagic telangiectasia: to transplant or not to transplant?. Liver International, 2016, 36, 1741-1744.	1.9	12
27	9q33.3q34.11 microdeletion: new contiguous gene syndrome encompassing STXBP1, LMX1B and ENG genes assessed using reverse phenotyping. European Journal of Human Genetics, 2016, 24, 830-837.	1.4	13
28	Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function. Human Molecular Genetics, 2015, 24, 1142-1154.	1.4	63
29	Genetic variation in the functional ENG allele inherited from the non-affected parent associates with presence of pulmonary arteriovenous malformation in hereditary hemorrhagic telangiectasia 1 (HHT1) and may influence expression of PTPN14. Frontiers in Genetics, 2015, 6, 67.	1.1	17
30	Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia. MAbs, 2015, 7, 630-637.	2.6	21
31	ELLIPSE Study. MAbs, 2014, 6, 793-798.	2.6	43
32	Genetic variants of $\langle i \rangle$ Adam17 $\langle i \rangle$ differentially regulate TGFÎ ² signaling to modify vascular pathology in mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 7723-7728.	3.3	44
33	ZEB2, a new candidate gene for asplenia. Orphanet Journal of Rare Diseases, 2014, 9, 2.	1.2	6
34	Hereditary hemorrhagic telangiectasia, liver vascular malformations and cardiac consequences. European Journal of Internal Medicine, 2013, 24, e35-e39.	1.0	40
35	Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output. JAMA - Journal of the American Medical Association, 2012, 307, 948-55.	3.8	301
36	Mouse and human strategies identify PTPN14 as a modifier of angiogenesis and hereditary haemorrhagic telangiectasia. Nature Communications, 2012, 3, 616.	5.8	64

#	Article	IF	CITATIONS
37	Pulmonary Vascular Disorders in Hereditary Hemorrhagic Telangiectasia. Progress in Respiratory Research, 2012, , 262-275.	0.1	1
38	Cerebral abscesses in hereditary haemorrhagic telangiectasia: A clinical and microbiological evaluation. Clinical Neurology and Neurosurgery, 2012, 114, 235-240.	0.6	66
39	Ex vivo study of bevacizumab transport through porcine nasal mucosa. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 465-469.	2.0	39
40	How to improve specific databases for clinical data in rare diseases? The example of hereditary haemorrhagic telangiectasia. Journal of Evaluation in Clinical Practice, 2012, 18, 523-527.	0.9	1
41	Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: A single-center study. Liver Transplantation, 2010, 16, 340-347.	1.3	73
42	High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and/or severe anemia. Gastrointestinal Endoscopy, 2010, 71, 760-767.	0.5	30
43	Acute paraplegia due to spinal arteriovenous fistula in two patients with hereditary hemorrhagic telangiectasia. European Journal of Pediatrics, 2009, 168, 135-139.	1.3	32
44	Evaluation of previously nonscreened hereditary hemorrhagic telangiectasia patients shows frequent liver involvement and early cardiac consequences. Hepatology, 2008, 48, 1570-1576.	3.6	48
45	Hemorrhagic Hereditary Telangiectasia (Rendu-Osler Disease) and Infectious Diseases: An Underestimated Association. Clinical Infectious Diseases, 2007, 44, 841-845.	2.9	80
46	Pulmonary Vascular Manifestations of Hereditary Hemorrhagic Telangiectasia (Rendu-Osler Disease). Respiration, 2007, 74, 361-378.	1.2	159